Latest News

Date Title Topic
20 May 2015 Pembrolizumab Seems to be a New Immune Checkpoint Inhibitor Option for NSCLC, However is our Knowledge on Tumour Biomarkers Enough? Lung and other thoracic tumours
18 May 2015 Annals of Oncology Press Release: World First – Researchers Quantify the Proportion of Different Genetic Mutations Contained within Individual Bowel Cancers Gastrointestinal cancers
12 May 2015 Lower Radiation Doses May Be Sufficient For Treating Certain Cancers, Report IAEA Experts Bioethics, legal and economic issues
08 May 2015 IMPAKT 2015 News: Molecular Screening of Patients with Metastatic Breast Cancer Can Be Carried-Out Across EU Countries Breast cancer - Personalised medicine
07 May 2015 IMPAKT 2015 News: PI3 Kinase and CDK4/6 Inhibitors Are Highly Active in ER-Positive Breast Cancer Breast cancer - Translational research - Anticancer agents & Biologic therapy
07 May 2015 IMPAKT 2015 News: A Circulating Tumour Cell Liquid Biopsy May Be Used for Non-Invasive Mutational Analysis in Patients with Breast Cancer Breast cancer - Translational research
07 May 2015 IMPAKT 2015 News: Constitutively Activated STAT3 May Be a Predictive Marker for Resistance to Trastuzumab in Patients with HER2 Positive Breast Cancer Breast cancer - Translational research - Anticancer agents & Biologic therapy
07 May 2015 IMPAKT 2015 News: Gene Expression Signatures May Signal Clinical Activity of Palbociclib in Patients with Breast Cancer Breast cancer - Translational research - Anticancer agents & Biologic therapy
Programme
28 Apr 2015 European Medicine Agency Recommends Refusal of the Marketing Authorisation for Dasiprotimut-T Haematologic malignancies - Cancer Immunology and Immunotherapy
27 Apr 2015 FDA Approves Ramucirumab for Metastatic Colorectal Cancer Gastrointestinal cancers - Anticancer agents & Biologic therapy
24 Apr 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Nivolumab Melanoma - Cancer Immunology and Immunotherapy
22 Apr 2015 Pembrolizumab Shows Antitumour Activity in Patients with Advanced NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
21 Apr 2015 Phase III Randomised Trial Shows Pembrolizumab Superiority When Compared to Ipilimumab in Patients with Advanced Melanoma Melanoma - Cancer Immunology and Immunotherapy
Consensus Guidelines Locally-advanced stage III non-small-cell lung cancer (NSCLC)